Skip to main content

Astatine Radiopharmaceuticals: Prospects and Problems.

Publication ,  Journal Article
Vaidyanathan, G; Zalutsky, MR
Published in: Curr Radiopharm
September 1, 2008

For the treatment of minimum residual diseases such micrometastases and residual tumor margins that remain after debulking of the primary tumor, targeted radiotherapy using radiopharmaceuticals tagged with alpha-particle-emitting radionuclides is very attractive. In addition to the their short range in tissue, which helps minimize harmful effects on adjacent normal tissues, alpha-particles, being high LET radiation, have several radiobiological advantages. The heavy halogen, astatine-211 is one of the prominent alpha-particle-emitting radionuclides in practice. Being a halogen, it can often be incorporated into biomolecules of interest by adapting radioiodination chemistry. A wide spectrum of compounds from the simple [(211)At]astatide ion to small organic molecules, peptides, and large proteins labeled with (211)At have been investigated with at least two reaching the stage of clinical evaluation. The chemistry, cytotoxic advantages, biodistribution studies, and microdosimetry/pharmacokinetic modeling of some of these agents will be reviewed. In addition, potential problems such as the harmful effect of radiolysis on the synthesis, lack of sufficient in vivo stability of astatinated compounds, and possible adverse effects when they are systemically administered will be discussed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Radiopharm

DOI

EISSN

1874-4729

Publication Date

September 1, 2008

Volume

1

Issue

3

Start / End Page

177

Location

United Arab Emirates

Related Subject Headings

  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaidyanathan, G., & Zalutsky, M. R. (2008). Astatine Radiopharmaceuticals: Prospects and Problems. Curr Radiopharm, 1(3), 177. https://doi.org/10.2174/1874471010801030177
Vaidyanathan, Ganesan, and Michael R. Zalutsky. “Astatine Radiopharmaceuticals: Prospects and Problems.Curr Radiopharm 1, no. 3 (September 1, 2008): 177. https://doi.org/10.2174/1874471010801030177.
Vaidyanathan G, Zalutsky MR. Astatine Radiopharmaceuticals: Prospects and Problems. Curr Radiopharm. 2008 Sep 1;1(3):177.
Vaidyanathan, Ganesan, and Michael R. Zalutsky. “Astatine Radiopharmaceuticals: Prospects and Problems.Curr Radiopharm, vol. 1, no. 3, Sept. 2008, p. 177. Pubmed, doi:10.2174/1874471010801030177.
Vaidyanathan G, Zalutsky MR. Astatine Radiopharmaceuticals: Prospects and Problems. Curr Radiopharm. 2008 Sep 1;1(3):177.

Published In

Curr Radiopharm

DOI

EISSN

1874-4729

Publication Date

September 1, 2008

Volume

1

Issue

3

Start / End Page

177

Location

United Arab Emirates

Related Subject Headings

  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1103 Clinical Sciences